{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:19:48Z","timestamp":1773998388729,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-125"],"award-info":[{"award-number":["V114C-125"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115C-098"],"award-info":[{"award-number":["V115C-098"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-110-PP52"],"award-info":[{"award-number":["CA-110-PP52"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-109-PP47"],"award-info":[{"award-number":["CA-109-PP47"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-108-PP46"],"award-info":[{"award-number":["CA-108-PP46"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114\\u20132314-B-075\\u2013001"],"award-info":[{"award-number":["NSTC 114\\u20132314-B-075\\u2013001"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113\\u20132634-F-039\\u2013001"],"award-info":[{"award-number":["NSTC 113\\u20132634-F-039\\u2013001"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031316","name":"Melissa Lee Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2026.116229","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T15:12:06Z","timestamp":1768144326000},"page":"116229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)"],"prefix":"10.1016","volume":"235","author":[{"given":"Nai-Jung","family":"Chiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Yeh","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.-Wei","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-8264","authenticated-orcid":false,"given":"Chung-Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9756-3974","authenticated-orcid":false,"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Fu","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Hui","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-4167","authenticated-orcid":false,"given":"Tai-Jan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Yu","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-3043","authenticated-orcid":false,"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-5189","authenticated-orcid":false,"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7167","authenticated-orcid":false,"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116229_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.116229_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116229_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116229_bib4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A Phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Cancer Chemother Pharm"},{"key":"10.1016\/j.ejca.2026.116229_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000527176","article-title":"Multicenter retrospective analysis of original versus modified FOLFIRINOX in metastatic pancreatic cancer: results of the NAPOLEON study","volume":"101","author":"Nakazawa","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2026.116229_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2023.100696","article-title":"Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation","volume":"47","author":"Su","year":"2024","journal-title":"Biomed J"},{"key":"10.1016\/j.ejca.2026.116229_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116229_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1440-1746.2005.03957.x","article-title":"Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer","volume":"21","author":"Shiah","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2026.116229_bib9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00280-009-0980-2","article-title":"Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil\/leucovorin (GOFL) in advanced pancreatic cancer","volume":"64","author":"Ch'ang","year":"2009","journal-title":"Cancer Chemother Pharm"},{"key":"10.1016\/j.ejca.2026.116229_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.10.023","article-title":"A multicenter, phase I\/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study","volume":"124","author":"Chiang","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116229_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bjc.1996.18","article-title":"Phase II study of gemcitabine in patients with advanced pancreatic cancer","volume":"73","author":"Carmichael","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116229_bib13","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1179\/joc.2008.20.1.119","article-title":"Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer","volume":"20","author":"Correale","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.ejca.2026.116229_bib15","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/annonc\/mdv603","article-title":"A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"27","author":"Ueno","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-024-01008-7","article-title":"Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan","volume":"31","author":"Cheng","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ejca.2026.116229_bib18","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: the human genomic variant search engine","volume":"35","author":"Kopanos","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2026.116229_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.ejca.2026.116229_bib20","article-title":"Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521","volume":"10","author":"Liao","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0021-9681(81)90007-2","article-title":"Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation","volume":"34","author":"Rubinstein","year":"1981","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ejca.2026.116229_bib22","unstructured":"Webpage: Survival Analysis: Comparison of Two Survival Curves \u2013 Rubinstein."},{"key":"10.1016\/j.ejca.2026.116229_bib23","article-title":"EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and\/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435)","volume":"38","author":"Chen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00936","article-title":"Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II\/III Trial","author":"Ohba","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib25","doi-asserted-by":"crossref","first-page":"S932","DOI":"10.1016\/j.annonc.2024.08.1590","article-title":"1527P GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised Phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116229_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116229_bib28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/cas.13883","article-title":"Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX","volume":"110","author":"Shirasu","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2026.116229_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100746","article-title":"The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan","volume":"8","author":"Su","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116229_bib30","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/cas.70087","article-title":"The C11orf24 gene as a useful biomarker for predicting severe neutropenia in modified FOLFIRINOX for pancreatic cancer","volume":"116","author":"Kanesada","year":"2025","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2026.116229_bib31","first-page":"2189","article-title":"Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience","volume":"12","author":"Su","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejca.2026.116229_bib32","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1097\/JS9.0000000000000495","article-title":"The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study","volume":"109","author":"Su","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejca.2026.116229_bib33","doi-asserted-by":"crossref","first-page":"S1252","DOI":"10.1016\/j.annonc.2024.08.2305","article-title":"LBA63 A randomized phase I\/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy","volume":"35","author":"Gehrels","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116229_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115424","article-title":"Phase 1\/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment","volume":"222","author":"Imaoka","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116229_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103033","article-title":"Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes","volume":"60","author":"Mizukami","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2026.116229_bib36","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","article-title":"Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma","volume":"26","author":"Yadav","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116229_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48721","article-title":"Prevalence of germline sequence variations among patients with pancreatic cancer in China","volume":"5","author":"Yin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.116229_bib38","article-title":"Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing","volume":"11","author":"Jiang","year":"2023","journal-title":"Mol Genet Genom Med"},{"key":"10.1016\/j.ejca.2026.116229_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s10038-022-01097-y","article-title":"Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients","volume":"68","author":"Matsubayashi","year":"2023","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ejca.2026.116229_bib40","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:39:41Z","timestamp":1773985181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"alternative-id":["S0959804926000092"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116229","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116229"}}